Canagliflozin
Canagliflozin is a pharmaceutical drug with 56 clinical trials. Currently 7 active trials ongoing. Historical success rate of 94.9%.
Success Metrics
Based on 37 completed trials
Phase Distribution
Phase Distribution
15
Early Stage
5
Mid Stage
26
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
92.5%
37 of 40 finished
7.5%
3 ended early
7
trials recruiting
56
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Canagliflozin Targeting Vascular Inflammation
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Clinical Trials (56)
Canagliflozin Targeting Vascular Inflammation
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
Genetics of Response to Canagliflozin
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer
Renal Mechanism of SGLT2 Inhibition
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Canagliflozin in Patients With Acute Decompansted Heart Failure
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Replication of the CANVAS Diabetes Trial in Healthcare Claims
Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 56